Skip to main content

Table 2 Factor for TMP-SMX discontinuation rate

From: Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study

Factor HR 95% CI P-value
Low-dose group (vs standard-dose) 0.18 0.04–0.86 0.032
Age (over 60 years) 2.54 0.56–11.5 0.230
Sex (men vs female) 1.61 0.56–4.7 0.380
Disease
 Hematological malignancy (reference) 1.00
 Autoimmune disease 1.37 0.29–6.4 0.690
 Other disease 0.26 0.02–3.4 0.310
Treatment
 Low PSL dose 1.00   
 High PSL dose 0.30 0.05–1.9 0.200
 Others 0 0–0 < 0.001
  1. The risk factors for TMP-SMX discontinuation using the Cox Fine and Gray method were described as adjusted hazard ratios and 95% CIs. The adjusted covariates were selected clinically and included the following: age, sex, dosage of TMP-SMX, and underlying disease
  2. Abbreviations: TMP-SMX trimethoprim-sulfamethoxazole, HR hazard ratio, CI confidence interval, PSL Prednisolone